Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: dalpiciclib plus letrozole
Sponsor: The Affiliated Hospital of Qingdao University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.